WHO Warns TB Funding Gap Threatens Global Progress

Tuberculosis killed an estimated 1.2 million people in 2024. That's a staggering number for a disease that's been curable with the right treatment for decades, and it's still the world's leading cause of death from a single infectious agent.

The WHO's Global Tuberculosis Report 2025, released in November 2025, actually contains some real progress. But WHO's own leadership is warning that this progress could unravel, and the reason comes down to money.

The Good News, First

Between 2023 and 2024, global TB incidence, meaning the rate at which people are newly falling ill, dropped by about 2%. TB deaths fell by roughly 3%. It was the first year in three years that new TB cases actually declined, which WHO officials read as a sign that health systems are finally recovering from the disruption COVID-19 caused to TB testing and treatment programs.

WHO Director-General Dr. Tedros Adhanom Ghebreyesus put it simply: "Progress is not victory." Zoom out to the bigger targets and the picture gets less encouraging. TB deaths fell 29% between 2015 and 2024, well short of the 75% reduction goal that was set for 2025. TB incidence dropped just 12% against a 50% target for the same period.

Where the Burden Actually Sits

This isn't an evenly distributed problem. In 2024, just eight countries accounted for two-thirds of all TB cases worldwide: India, Indonesia, the Philippines, China, Pakistan, Nigeria, the Democratic Republic of the Congo, and Bangladesh.

India alone made up 25% of the global TB burden, more than any other single country. If you're reading this from India, that statistic isn't abstract. It's a fair bet that TB has touched someone in your extended community, whether or not it's ever come up in conversation, since stigma around the disease still keeps a lot of it quiet.

The Funding Problem, Explained Plainly

Here's the number that explains WHO's warning. In 2024, only $5.9 billion was available globally for TB prevention, diagnosis, and treatment. The annual target set for 2027 is $22 billion. That means current funding sits at just over a quarter of what's actually needed.

It gets worse from there. As of mid-2025, the Global Fund's 2024–2026 grant cycle, one of the largest sources of international TB funding, had already been cut by $1.4 billion, about 11% of what was originally allocated. The United States alone accounted for roughly half of all international donor funding for TB in 2024, and about a fifth of total global TB funding overall, so reductions in U.S. contributions carry outsized weight on the global numbers.

None of this is abstract policy talk if you're one of the estimated 390,000 people worldwide with drug-resistant TB. Only about 2 in 5 of those cases, roughly 164,545 people, are currently being diagnosed and treated. That gap exists largely because drug-resistant TB testing and treatment infrastructure is expensive to build and maintain, and it's exactly the kind of program that funding cuts hit first.

Why This Matters Beyond the Headline Numbers

In clinical settings, funding gaps at the policy level eventually show up as very concrete problems: fewer diagnostic machines running, longer waits for drug-resistant TB test results, and community health workers stretched across more patients than they can realistically manage. It's easy to read a report like this as a distant Geneva press release, but the actual effect lands in local clinics and testing centers.

The report also flagged something worth knowing if TB runs in your community: social protection coverage for TB patients, things like income support during treatment, varies wildly by country. Among the 30 highest-burden countries, coverage ranged from just 3.1% in Uganda to 94% in Mongolia, and 19 of those 30 countries have coverage below half their TB patients. Treatment for TB typically runs six months or longer, and financial strain during that window is one of the biggest reasons people stop treatment early, which in turn drives drug resistance.

What This Means for You, Practically

TB is curable, and that hasn't changed. What has changed is how much strain the systems delivering that cure are currently under.

If you have a persistent cough lasting more than two to three weeks, unexplained weight loss, night sweats, or fatigue that isn't improving, these are worth getting checked rather than waiting out. A pulmonologist can evaluate persistent respiratory symptoms directly, or you can start with a general physician for an initial assessment and referral. TB diagnosis typically involves sputum testing or imaging, which a diagnostic center can arrange.

If you're already on TB treatment, the single most important thing you can do is finish the full course, even once you start feeling better. Stopping early is one of the main drivers of drug-resistant TB, and it's a completely avoidable one. If access or cost is a barrier partway through treatment, raise it with your treating hospital or clinic rather than quietly stopping, since many programs have support options that aren't always advertised upfront.